Masaki Nakamura

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4517388/publications.pdf

Version: 2024-02-01

		1040056	1125743
29	250	9	13
papers	citations	h-index	g-index
20	20	20	245
29	29	29	345
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma. BMC Cancer, 2020, 20, 336.	2.6	27
2	Dosimetric factors predicting radiation pneumonitis after CyberKnife stereotactic body radiotherapy for peripheral lung cancer. British Journal of Radiology, 2016, 89, 20160560.	2.2	25
3	Impact of EGFR Mutation and ALK Translocation on Recurrence Pattern After Definitive Chemoradiotherapy for Inoperable Stage III Non-squamous Non–small-cell Lung Cancer. Clinical Lung Cancer, 2019, 20, e256-e264.	2.6	22
4	Clinical log data analysis for assessing the accuracy of the CyberKnife fiducial-free lung tumor tracking system. Practical Radiation Oncology, 2018, 8, e63-e70.	2.1	18
5	Pattern of recurrence after CyberKnife stereotactic body radiotherapy for peripheral early non-small cell lung cancer. Journal of Thoracic Disease, 2019, 11, 214-221.	1.4	15
6	PARP inhibitor olaparib sensitizes esophageal carcinoma cells to fractionated proton irradiation. Journal of Radiation Research, 2020, 61, 177-186.	1.6	14
7	Hypofractionated proton beam therapy for centrally located lung cancer. Journal of Medical Imaging and Radiation Oncology, 2019, 63, 552-556.	1.8	12
8	Comparative analysis of the immune responses in cancer cells irradiated with X-ray, proton and carbon-ion beams. Biochemical and Biophysical Research Communications, 2021, 585, 55-60.	2.1	11
9	Additional chemotherapy improved local control and overall survival after stereotactic body radiation therapy for patients with oligo-recurrence. Radiation Oncology, 2018, 13, 75.	2.7	10
10	Toxicity of Radiosurgery for Brainstem Metastases. World Neurosurgery, 2018, 119, e757-e764.	1.3	10
11	Investigation of the efficacy and safety of CyberKnife hypofractionated stereotactic radiotherapy for brainstem metastases using a new evaluation criterion: †symptomatic controlâ€. Journal of Radiation Research, 2017, 58, 834-839.	1.6	9
12	Liquid Biopsy Cell-free DNA Biomarkers in Patients With Oligometastatic Colorectal Cancer Treated by Ablative Radiotherapy. Anticancer Research, 2021, 41, 829-834.	1.1	9
13	Radiation pneumonitis after palliative radiotherapy in cancer patients with interstitial lung disease. Radiotherapy and Oncology, 2021, 161, 47-54.	0.6	8
14	Prospective evaluation of XRCCâ€1 Arg194Trp polymorphism as bioâ€predictor for clinical outcome in locally advanced laryngeal cancer undergoing cisplatinâ€based chemoradiation. Head and Neck, 2020, 42, 1045-1056.	2.0	7
15	Impacts of the STINGâ€IFNAR1â€STAT1â€IRF1 pathway on the cellular immune reaction induced by fractionated irradiation. Cancer Science, 2022, 113, 1352-1361.	3.9	7
16	Identification of the mutation signature of the cancer genome caused by irradiation. Radiotherapy and Oncology, 2021, 155, 10-16.	0.6	6
17	Impact of prophylactic cranial irradiation on pattern of brain metastases as a first recurrence site for limited-disease small-cell lung cancer. Journal of Radiation Research, 2018, 59, 767-773.	1.6	5
18	Frequency and predictors of detecting early locoregional recurrence/disease progression of oral squamous cell carcinoma with high-risk factors on imaging tests before postoperative adjuvant radiotherapy. International Journal of Clinical Oncology, 2019, 24, 1182-1189.	2.2	5

#	Article	IF	CITATIONS
19	Dose–Volume and Radiobiological Model-Based Comparative Evaluation of the Gastrointestinal Toxicity Risk of Photon and Proton Irradiation Plans in Localized Pancreatic Cancer Without Distant Metastasis. Frontiers in Oncology, 2020, 10, 517061.	2.8	5
20	Late radiological changes after passive scattering proton beam therapy for Stage I lung cancer. Journal of Radiation Research, 2018, 59, 456-461.	1.6	4
21	Comparison of a Hybrid IMRT/VMAT technique with non-coplanar VMAT and non-coplanar IMRT for unresectable olfactory neuroblastoma using the RayStation treatment planning system—EUD, NTCP and planning study. Journal of Radiation Research, 2021, 62, 540-548.	1.6	4
22	Efficacy and safety of accelerated fractionated radiotherapy without elective nodal irradiation for T3NO glottic cancer without vocal cord fixation. Head and Neck, 2020, 42, 1775-1782.	2.0	4
23	Differences in failure patterns according to the EGFR mutation status after proton beam therapy for early stage non-small cell lung cancer. Radiotherapy and Oncology, 2020, 149, 14-17.	0.6	3
24	Long-term clinical outcomes of patients diagnosed with pT1a-muscularis mucosae with lymphovascular invasion or pT1b after endoscopic resection for cT1N0M0 esophageal squamous cell carcinoma. Esophagus, 2021, , 1.	1.9	3
25	Palliative Radiation Therapy for Macroscopic Hematuria Caused by Urothelial Cancer. Palliative Medicine Reports, 2020, 1, 201-207.	0.9	2
26	Radiobiological model-based approach to determine the potential of dose-escalated robust intensity-modulated proton radiotherapy in reducing gastrointestinal toxicity in the treatment of locally advanced unresectable pancreatic cancer of the head. Radiation Oncology, 2020, 15, 157.	2.7	2
27	Comprehensive screening for drugs that modify radiation-induced immune responses. British Journal of Cancer, 2022, , .	6.4	2
28	Could excision repair crossâ€complementing groupâ€1 mRNA expression from peripheral blood lymphocytes predict locoregional failure with cisplatin chemoradiation for locally advanced laryngeal cancer?. Asia-Pacific Journal of Clinical Oncology, 2020, 16, e19-e26.	1.1	1
29	Impact of Proton Beam Irradiation of an Anatomic Subsegment of the Liver for Hepatocellular Carcinoma. Practical Radiation Oncology, 2020, 10, e264-e271.	2.1	O